Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Profit After Tax (2016 - 2026)

Cytosorbents filings provide 15 years of Profit After Tax readings, the most recent being -$5.5 million for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 27.36% to -$5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.2 million, a 60.43% increase, with the full-year FY2025 number at -$8.2 million, up 60.43% from a year prior.
  • Profit After Tax hit -$5.5 million in Q4 2025 for Cytosorbents, down from -$3.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $15.3 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • Median Profit After Tax over the past 5 years was -$5.8 million (2024), compared with a mean of -$4.7 million.
  • Biggest five-year swings in Profit After Tax: tumbled 1273.27% in 2021 and later skyrocketed 2102.15% in 2023.
  • Cytosorbents' Profit After Tax stood at -$9.3 million in 2021, then surged by 91.77% to -$766126.0 in 2022, then skyrocketed by 2102.15% to $15.3 million in 2023, then tumbled by 149.33% to -$7.6 million in 2024, then grew by 27.36% to -$5.5 million in 2025.
  • The last three reported values for Profit After Tax were -$5.5 million (Q4 2025), -$3.2 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.